Status:
COMPLETED
Aripiprazole Oral Acceptability Trial
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Stable patients currently receiving aripiprazole or other antipsychotic medications.
Exclusion
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT00101569
Start Date
March 1 2004
End Date
March 1 2005
Last Update
November 8 2013
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Anaheim, California, United States
2
Local Institution
National City, California, United States
3
Local Institution
North Miami Beach, Florida, United States
4
Local Institution
Overland Park, Kansas, United States